Danish allergy company ALK-Abelló has entered into a strategic partnership with China-based biopharmaceutical firm GenSci to develop and commercialize its house dust mite allergy immunotherapy (AIT) products in China. Under the agreement, GenSci has secured exclusive rights to ALK’s AIT products, Alutard® and ACARIZAX®, until the end of 2039.
This collaboration will see GenSci assume responsibility for sales, marketing, and most of the clinical development and registration costs, while ALK will continue to manage the production and supply of these products.
ALK will receive an upfront payment of approximately DKK 245 million and is eligible for milestone payments of up to DKK 1.3 billion in total. Although this partnership is not expected to significantly affect ALK’s 2025 earnings, it is projected to enhance the company’s margins in the medium term. ALK’s CEO, Peter Halling, expressed optimism about the partnership, highlighting the potential for accelerating the market uptake of their evidence-based AIT products in China.
With China having the largest population suffering from house dust mite allergies globally, yet with fewer than one million people currently receiving AIT treatment, the partnership aims to expand market penetration through awareness campaigns, hospital collaborations, and digital healthcare initiatives, ultimately increasing access to vital allergy treatments.
